A novel NSAID derivative, phospho-ibuprofen, prevents AOM-induced colon cancer in rats

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 643-650

  Ouyang, Nengtai ^a   Ji, Ping ^a   Williams, Jennie L ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

catenin; Azoxymethane; Colon cancer; COX 2; NF B; Non steroid anti inflammatory drug

Indexed keywords

AZOXYMETHANE; BETA CATENIN; CYCLOOXYGENASE 2; IBUPROFEN; IBUPROFEN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHO IBUPROFEN; PROSTAGLANDIN E2; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; HISTOLOGY; IMMUNOFLUORESCENCE; IN VITRO STUDY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STOMACH ULCER; TREATMENT DURATION; WESTERN BLOTTING;

ABERRANT CRYPT FOCI; ANIMALS; ANTICARCINOGENIC AGENTS; AZOXYMETHANE; BETA CATENIN; CARCINOGENS; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IBUPROFEN; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; ORGANOPHOSPHATES; RATS;

EID: 84873627082     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1756     Document Type: Article

References (51)

1. Johnson CC, Hayes RB, Schoen RE, Gunter MJ and Huang WY; PLCO Trial Team: Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Gastroenterol 105: 2646 2655, 2010.
2. Harris RE, Beebe-Donk J and Alshafie GA: Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 8: 237, 2008.
3. Harris RE, Beebe-Donk J, Doss H and Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (Review). Oncol Rep 13: 559-583, 2005.
4. Cioli V, Putzolu S, Rossi V and Corradino C: A toxicological and pharmacological study of ibuprofen guaiacol ester (AF 2259) in the rat. Toxicol Appl Pharmacol 54: 332-339, 1980.
5. Venuti MC, Young JM, Maloney PJ, Johnson D and McGreevy K: Synthesis and biological evaluation of omega-(N, N, N-trialkylammonium)alkyl esters and thioesters of carboxylic acid nonsteroidal antiinflammatory agents. Pharm Res 6: 867-873, 1989.
6. Samara E, Avnir D, Ladkani D and Bialer M: Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharm Drug Dispos 16: 201-210, 1995.
7. Abordo EA, Bowden K, Huntington AP and Powell SL: Prodrugs. Part 3. 2-Formylphenyl esters of indomethacin, ketoprofen and ibuprofen and 6-substituted 2-formyl and 2-acylphenyl esters of aspirin. Farmaco 53: 95-101, 1998.
8. Mahfouz NM, Omar FA and Aboul-Fadl T: Cyclic amide derivatives as potential prodrugs II: N-hydroxy-methylsuccinimide-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic index. Eur J Med Chem 34: 551-562, 1999.
9. Kahns AH, Jensen PB, Mork N and Bundgaard H: Kinetics of hydrolysis of indomethacin and indomethacin ester prodrugs in aqueous solution. Acta Pharm Nord 1: 327-336, 1989.
10. Wang LF, Chiang HN and Wu PC: Kinetics and hydrolysis mechanism of polymeric prodrugs containing ibuprofen, ketoprofen, and naproxen as pendent agents. J Biomater Sci Polym Ed 13: 287-299, 2002.
11. Peng YS, Lin SC, Huang SJ, et al: Chondroitin sulfate-based anti-inflammatory macromolecular prodrugs. Eur J Pharm Sci 29: 60-69, 2006.
12. Zhao X, Tao X, Wei D and Song Q: Pharmacological activity and hydrolysis behavior of novel ibuprofen glucopyranoside conjugates. Eur J Med Chem 41: 1352-1358, 2006.
13. Kourounakis PN, Tsiakitzis K, Kourounakis AP and Galanakis D: Reduction of gastrointestinal toxicity of NSAIDs via molecular modifications leading to antioxidant anti-inflammatory drugs. Toxicology 144: 205-210, 2000.
14. Galanakis D, Kourounakis AP, Tsiakitzis KC, et al: Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity. Bioorg Med Chem Lett 14: 3639-3643, 2004.
15. Yeh RK, Chen J, Williams JL, et al: NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67: 2197-2205, 2004.
16. Kashfi K, Ryan Y, Qiao LL, et al: Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther 303: 1273-1282, 2002.
17. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F and Rigas B: Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 61: 3285-3289, 2001.
18. Mattheolabakis G, Nie T, Constantinides PP and Rigas B: Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation. Pharm Res 29: 1435-1443, 2012.
19. Sun Y, Huang L, Mackenzie GG and Rigas B: Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338: 775-783, 2011.
20. Xie G, Sun Y, Nie T, et al: Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337: 876-886, 2011.
21. Huang L, Mackenzie G, Ouyang N, et al: The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol 162: 1521-1533, 2011.
22. Wong CC, Cheng KW, Xie G, et al: Carboxylesterases 1 and 2 hydrolyze phospho-NSAIDs: relevance to their pharmacological activity. J Pharmacol Exp Ther 340: 422-432, 2012.
23. Piazza GA, Keeton AB, Tinsley HN, et al: A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila) 2: 572-580, 2009.
24. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-151, 1987.
25. Natarajan K, Singh S, Burke TR Jr, Grunberger D and Aggarwal BB: Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappaB. Proc Natl Acad Sci USA 93: 9090-9095, 1996.
26. Williams JL, Ji P, Ouyang N, Liu X and Rigas B: NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice. Carcinogenesis 29: 390-397, 2008.
27. Shanbhag VR, Crider AM, Gokhale R, Harpalani A and Dick RM: Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity. J Pharm Sci 81: 149-154, 1992.
28. Antonakopoulos N and Karamanolis DG: The role of NSAIDs in colon cancer prevention. Hepatogastroenterology 54: 1694-1700, 2007.
29. Backlund MG, Mann JR and Dubois RN: Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 69 (Suppl 1): 28-32, 2005.
30. Koki A, Khan NK, Woerner BM, et al: Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 507: 177-184, 2002.
31. Koch A, Gustafsson B, Fohlin H and Sorenson S: Cyclooxygenase-2 expression in lung cancer cells evaluated by immunocytochemistry. Diagn Cytopathol 39: 188-193, 2011.
32. Schoen RT and Vender RJ: Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 86: 449-458, 1989.
33. Mitchell JA and Warner TD: Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128: 1121-1132, 1999.
34. Wallace JL and Cirino G: The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 15: 405-406, 1994.
35. Kardosh A, Blumenthal M, Wang WJ, Chen TC and Schonthal AH: Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 3: 55-62, 2004.
36. Narayanan BA, Condon MS, Bosland MC, Narayanan NK and Reddy BS: Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 9: 3503-3513, 2003.
37. Grosch S, Tegeder I, Niederberger E, Brautigam L and Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744, 2001.
38. Maier TJ, Schilling K, Schmidt R, Geisslinger G and Grosch S: Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67: 1469-1478, 2004.
39. Arico S, Pattingre S, Bauvy C, et al: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277: 27613-27621, 2002.
40. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403, 2000.
41. Ostrowski J, Wocial T, Skurzak H and Bartnik W: Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors? Br J Cancer 88: 1143-1151, 2003.
42. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64: 2030-2038, 2004.
43. Zhang YJ, Bao YJ, Dai Q, et al: mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol 18: 580-588, 2011.
44. Wang X, Baek SJ and Eling T: COX inhibitors directly alter gene expression: role in cancer prevention? Cancer Metastasis Rev 30: 641-657, 2011.
45. Petrescu I and Tarba C: Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim Biophys Acta 1318: 385-394, 1997.
46. Somasundaram S, Sigthorsson G, Simpson RJ, et al: Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 14: 639-650, 2000.
47. Das S, Khan N, Mukherjee S, et al: Redox regulation of resveratrol-mediated switching of death signal into survival signal. Free Radic Biol Med 44: 82-90, 2008.
48. Vaish V, Tanwar L and Sanyal SN: The role of NF-kappaB and PPARgamma in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. Tumour Biol 31: 427-436, 2010.
49. Maier TJ, Janssen A, Schmidt R, Geisslinger G and Grosch S: Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2- independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 19: 1353-1355, 2005.
50. Paul S, DeCastro AJ, Lee HJ, et al: Dietary intake of pterostilbene, a constituent of blueberries, inhibits the beta-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis 31: 1272-1278, 2010.
51. Onizawa M, Nagaishi T, Kanai T, et al: Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 296: G850-G859, 2009.